Metabolism
Obesity and weight management, metabolic syndrome and insulin resistance, MASLD/fatty liver, and nutrition and lifestyle evidence.
Atrial Fibrillation and Semaglutide in Obesity-Related HFpEF: STEP-HFpEF Subgroup Analysis
Prespecified subgroup analysis of the pooled STEP-HFpEF Program testing whether atrial fibrillation modifies semaglutide's effect on symptoms in obesity-related HFpEF. PICO summary and expert commentary.
Semaglutide and Cardiac Remodeling in Obesity-Related HFpEF
An echocardiography substudy of the STEP-HFpEF Program found once-weekly semaglutide 2.4 mg attenuated adverse cardiac remodeling versus placebo over 52 weeks. PICO summary and expert commentary.
Semaglutide in Obesity-Related HFpEF: Effect of Baseline Atrial Fibrillation (STEP-HFpEF Program)
A pooled secondary analysis of the STEP-HFpEF and STEP-HFpEF DM trials examined whether baseline atrial fibrillation modified the benefit of once-weekly semaglutide 2.4 mg in obesity-related HFpEF. PICO summary and expert commentary.
Semaglutide 2.4 mg and Physical Functioning: Patient-Reported Outcomes from the STEP 1-4 Trials
Pooled patient-reported outcomes from the STEP 1-4 trials show semaglutide 2.4 mg improved physical functioning versus placebo over 68 weeks. PICO summary and expert commentary.
Semaglutide and long-term weight loss in obesity without diabetes (SELECT trial)
A prespecified analysis of the SELECT randomised trial showing sustained four-year weight loss with semaglutide versus placebo in adults with cardiovascular disease and obesity but no diabetes. PICO summary and expert commentary.
SELECT Kidney Outcomes
Secondary analysis of the SELECT trial finds once-weekly semaglutide 2.4 mg modestly lowered a composite kidney endpoint versus placebo in adults with overweight or obesity and cardiovascular disease but no diabetes. PICO summary and expert commentary.
STEP-HFpEF
Prespecified pooled analysis of the STEP-HFpEF program: once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.